Key result
Daily treatment with the angiotensin type 1 receptor antagonist losartan significantly reduced MPTP-induced loss of dopaminergic neurons in the substantia nigra pars compacta of mice from 61.8% to 25.0%.
Why the study?
Does losartan prevent MPTP-induced degeneration of dopaminergic neurons in preclinical models of Parkinson's disease?
Does losartan prevent MPTP-induced degeneration of dopaminergic neurons in preclinical models of Parkinson's disease?
Absolute Event Rate: 25% vs 61.8%
p-value: p=<0.05
Losartan demonstrates neuroprotective effects against MPTP-induced dopaminergic neuronal loss in preclinical models of Parkinson's disease.
No takes yet. Share an insight, caveat, or question.
Losartan neuroprotection in PD models; hypothesis-generating and leaves open clinical translation.
Grammatopoulos et al. (2007) studied Parkinson's disease (MPTP model). Losartan vs. Saline or media (with MPTP/MPP+) was evaluated on Loss of dopaminergic (TH+) neurons in the substantia nigra pars compacta (p=<0.05). Daily treatment with the angiotensin type 1 receptor antagonist losartan significantly reduced MPTP-induced loss of dopaminergic neurons in the substantia nigra pars compacta of mice from 61.8% to 25.0%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: